学术探索
学术期刊
新闻热点
数据分析
智能评审

New cytotoxic agents and schedules for advanced breast cancer

被引：21
作者：
Burstein, HJ
Bunnell, CA
Winer, EP
机构：
[1] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA
来源：
SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 04期
关键词：
D O I：
10.1053/sonc.2001.26146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：344 / 358
页数：15
相关论文
共 170 条
[1]   A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer [J].
Adachi, I ;
Watanabe, T ;
Takashima, S ;
Narabayashi, M ;
Horikoshi, N ;
Aoyama, H ;
Taguchi, T .
BRITISH JOURNAL OF CANCER, 1996, 73 (02) :210-216
[2]  
ALVAREZ AM, 1999, P AN M AM SOC CLIN, V18, P165
[3]  
[Anonymous], P AM SOC CLIN ONCOLO
[4]   PHASE I-II STUDIES OF ORAL TEGAFUR (FTORAFUR) [J].
ANSFIELD, FJ ;
KALLAS, GJ ;
SINGSON, JP .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (02) :107-110
[5]   Docetaxel: Response in patients who have received at least two prior chemotherapy regimes for metastatic breast cancer [J].
Archer, CD ;
Lowdell, C ;
Sinnett, HD ;
English, J ;
Khan, S ;
Coombes, RC .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) :816-819
[6]  
ATIENZA DM, 1995, CANCER, V76, P2485, DOI 10.1002/1097-0142(19951215)76:12<2485::AID-CNCR2820761212>3.0.CO
[7]  
2-J
[8]   VINORELBINE AS SINGLE-AGENT IN PRETREATED PATIENTS WITH ADVANCED BREAST-CANCER [J].
BARNI, S ;
ARDIZZOIA, A ;
BERNARDO, G ;
VILLA, S ;
STRADA, MR ;
CAZZANIGA, M ;
ARCHILI, C ;
FRONTINI, L .
TUMORI, 1994, 80 (04) :280-282
[9]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[10]  
BATIST G, 1998, P AN M AM SOC CLIN, V17, P115
12345678910